BIIB
BiogenBiogen is a biotechnology name in the health care sector. Over the past year it returned +63.0%, against +16.3% over three months and +9.1% over one. It trades 18.3% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 35.4% is above the market's typical range.
Its worst peak-to-trough decline over the year was -14.3%, and it has traded a median $200M a day — the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.09 with the S&P 500 proxy, so it has been moving substantially on its own.
How BIIB scores on all four profiles
Its standing on steadiness, defensiveness and rebound — plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.
Start a free 7-day trial| 1 day | +4.2% |
| 1 week | +6.1% |
| 1 month | +9.1% |
| 3 months | +16.3% |
| 6 months | +14.1% |
| 1 year | +63.0% |
| 12-1 momentum | +49.5% |
| Volatility (1y, annualized) | 35.4% |
| Max drawdown (1y) | -14.3% |
| Distance vs 200-day average | +18.3% |
| Return per unit of risk | 1.78 |
| Median daily dollar volume | $200M |
Get BIIB when it shows up in a ranking
Two editions a weekday, free — ranked lists built from this same data, on whatever the market is talking about.
Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.